Innovent diversifies pipeline with China rights to three Incyte compounds

Innovent Biologics Inc. (HKSE:1801) added three targets and a new modality to its pipeline following a deal for Chinese rights to three clinical cancer compounds from Incyte Corp. (NASDAQ:INCY).

The biotech will get rights in China, Hong Kong, Macau and Taiwan to develop and commercialize small molecules pemigatinib (INCB54828), itacitinib (INCB39110) and parsaclisib (INCB50465) for hematological and oncology indications. Prior to the deal, Innovent's pipeline included only antibodies...